Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding

Figures & data

Figure 1 Work productivity impairment values at baseline and EOT as measured using the modified Work Productivity and Activity Impairment (mWPAI) questionnaire.

Note: Value of “0” indicate no impairment due to heavy menstrual bleeding and value of “10” indicate complete work productivity impairment (ie, prevents undertaking any work).
Abbreviation: EOT, end of treatment; AUS, Australia; CZR, Czech Republic; FIN, Finland; GER, Germany; HUN, Hungary; NL, The Netherlands; PL, Poland; SWE, Sweden; UK, United Kingdom; UKR, Ukraine.

Figure 2 Activities of daily living impairment values at baseline and EOT as measured using the modified Work Productivity and Activity Impairment (mWPAI) questionnaire.

Note: Value of “0” indicate no impairment due to HMB and value of “10” indicate complete impairment of activities of daily living (ie, prevents undertaking any usual activities).
Abbreviations: EOT, end of treatment; E₂V/DNG, estradiol-valerate/dienogest; AUS, Australia; CZR, Czech Republic; FIN, Finland; GER, Germany; HUN, Hungary; NL, The Netherlands; PL, Poland; SWE, Sweden; UK, United Kingdom; UKR, Ukraine.

Figure 3 Reduction in work productivity and activities of daily living impairment across all countries (baseline to end of treatment) by treatment group (negative values indicate improvement).

Abbreviation: E₂V/DNG, estradiol-valerate/dienogest.

Table 1 Change in work productivity and activities in daily living from baseline to end of treatment (baseline results from bootstrapping; end of treatment results from Bayesian analysis)

Country	Change in work productivity (%)		Change in activities of daily living (%)
	E2V/DNG	Placebo	E2V/DNG	Placebo
AUS	−43.91%	−13.18%	−45.59%	−15.12%
CZR	−56.96%	−30.43%	−56.97%	−32.52%
FIN	−53.86%	−29.88%	−62.82%	−42.58%
GER	−55.45%	−27.17%	−60.66%	−37.73%
HUN	−57.11%	−26.57%	−63.60%	−42.15%
NL	−38.86%	−2.79%	−51.62%	−23.49%
PL	−56.94%	−25.55%	−57.32%	−29.10%
SWE	−23.83%	11.58%	−59.97%	−39.57%
UK	−17.89%	25.78%	−42.83%	−14.23%
UKR	−55.46%	−32.49%	−54.48%	−31.24%
Average	−46.03%	−15.07%	−55.59%	−30.77%

Notes: Negative change implies improvement in work productivity or activities of daily living.

Abbreviations: AUS, Australia; CZR, Czech Republic; FIN, Finland; GER, Germany; HUN, Hungary; NL, The Netherlands; PL, Poland; SWE, Sweden; UK, United Kingdom; UKR, Ukraine; E₂V/DNG, estradiol-valerate/dienogest.

Table 2 Savings due to E₂V/DNG treatment related to improvements in work productivity and activities of daily living, in 2008 local currency and US dollars

	Loss at baseline	Loss at EOT for E2V/DNG group	Loss at EOT for placebo group	Monthly savings due to E2V/DNG treatment	Monthly savings due to E2V/DNG treatment (US$)#
Work productivity
UK	£129.1	£77.6	£118.8	£41.3	US$61.9
Germany	€195.8	€64.6	€105.6	€41.0	US$47.2
Czech Republic	CZK 1954.6	CZK 722.2	CZK 1167.3	CZK 445.0	US$29.3
Hungary	HUF 15,931.0	HUF 4458.0	HUF 7631.5	HUF 3173.5	US$22.1
Poland	PLN 444.1	PLN 145.9	PLN 252.2	PLN 106.3	US$52.3
Sweden	SEK 1029.6	SEK 619.9	SEK 908.0	SEK 288.1	US$31.3
ADL impairment
UK	£177.7	£74.3	£111.5	£37.2	US$55.8
Germany	€233.1	€67.9	€107.5	€39.6	US$45.6
Czech Republic	CZK 1931.0	CZK 713.3	CZK 1118.6	CZK 405.3	US$26.7
Hungary	HUF 17,900.0	HUF 4250.7	HUF 6755.6	HUF 2504.9	US$17.5
Poland	PLN 390.8	PLN 127.2	PLN 211.3	PLN 84.1	US$41.4
Sweden	SEK 1952.4	SEK 617.6	SEK 932.5	SEK 314.8	US$34.2

Note:

# Purchasing power parity US$, in 2008.¹⁶

Abbreviations: ADL, activities of daily living; EOT, end-of-treatment; E₂V/DNG, estradiol-valerate/dienogest.

United Nations Statistics DivisionPurchasing power parities (PPP) conversion factor, local currency unit to international dollarMillennium development goals indicators2010 Available from: http://unstats.un.org/unsd/mdg/SeriesDetail.aspx?srid=699Accessed March 3, 2011

 Google Scholar